US › Healthcare

ZyVersa Therapeutics Inc. (ZVSA)

US · Healthcare · Biotechnology

$0.10-0.99%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-1.8M

Profit YoY

+20.5%

EPS

$-2.56

EPS estimate

$-0.25

EPS came in at -2.56 against a street estimate of -0.25 — a miss of 924.0%.

Key statistics

Market cap

$817,688

Forward P/E

0.0

P/B

0.21

Book value

$-1.45

EPS (TTM)

$-3.67

52-week high

$0.30

52-week low

$0.10

50-day MA

$0.15

200-day MA

$0.18

Beta

0.83

Analyst view

Analysts rate ZyVersa Therapeutics Inc. a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $20.00.

Shareholding

Insiders

0.02%

Institutions

5.15%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for ZyVersa Therapeutics Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.